human immunodeficiency virus

(Indiana University School of Medicine) One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system.

Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.

(Aeras) Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus (HIV).

The trial will be conducted at research sites in Senegal and South Africa with primary funding support from the European and Developing Countries Clinical Trials Partnership (EDCTP).

The number of people living with the human immunodeficiency virus (HIV), the virus that causes AIDS, continues to rise.

That’s mainly because of highly effective drugs that allow people infected with HIV to live longer, healthier lives, the CDC says.

VANCOUVER (MedPage Today) -- The gaps in diabetes care among patients diagnosed with human immunodeficiency virus infection are wide enough to drive trucks through, researchers said here at the annual meeting of the Infectious Diseases Society of America.

VANCOUVER (MedPage Today) -- The government message to test most people for human immunodeficiency virus infection appears to have fallen on deaf ears at the largest U.S. healthcare network: the Veterans Affairs health system.

VIENNA (MedPage Today) -- Once-daily dosing of maraviroc (Selzentry), a cell entry inhibitor, with the boosted protease inhibitor atazanavir (Reyataz) may be sufficient to suppress human immunodeficiency virus (HIV) among treatment naive patients, according to results from a pilot study.

VIENNA (MedPage Today) -- Researchers said here that therapeutic drug monitoring to assure proper levels of protease inhibitors are on board should be considered when non-nucleoside reverse transcriptase inhibitors are added to antiretroviral regimens for experienced human immunodeficiency virus (HIV) patients.

BUENOS AIRES (MedPage Today) -- The incidence of nontraumatic intracranial bleeding -- one of the feared consequences of hemophilia -- appears numerically higher in patients who are also infected with the human immunodeficiency virus (HIV), researchers reported here.

The Centers for Medicare & Medicaid Services (CMS) today announced its final decision to cover Human Immunodeficiency Virus (HIV) infection screening for Medicare beneficiaries who are at increased risk for the infection, including women who are pregnant and Medicare beneficiaries of any age who voluntarily request the service.

A falling CD4 count predicted increased susceptibility to seven types of cancer in people infected with human immunodeficiency virus (HIV), according to a study of more than 50,000 patients.